摘要
目的探讨重组人白介素-11联合环孢素治疗糖皮质激素无效原发免疫性血小板减少症(ITP)的临床疗效。方法将在庐江县人民医院住院的激素治疗无效的ITP患者44例,随机分成对照组和实验组,每组22例。研究组患者采用重组人白介素-11联合环孢素治疗;对照组患者采用长春新碱联合人免疫球蛋白治疗。测定治疗前和治疗后3、7、14、21天,1、3、5、12个月两组患者的血小板计数,观察两组患者的临床疗效和不良反应情况。结果治疗前和治疗3天后,与对照组比较,研究组患者血小板计数有增高趋势,但差异无统计学意义(P>0.05);治疗7、14、21天,1、3、5、12个月后,与对照组比较,研究组患者的血小板计数升高,差异有统计学意义(P<0.05)。治疗1、3、5、12个月后,与对照组比较,研究组患者的有效率升高,且各时间段的差异均有统计学意义(P<0.05),少数患者出现胃肠道症状、轻度肝肾功能损害和血压升高等不良反应。结论采用重组人白介素-11联合环孢素治疗糖皮质激素无效ITP安全有效。
Objective To investigate the clinical effect of recombinant human interleukin-11 combined with cyclosporine in the treatment of primary immune thrombocytopenia（ITP） with ineffective glucocorticoid. Methods Forty-four ITP patients admitted to Lujiang county people＇s hospital were randomly divided into the control group and the experimental group, with 22 patients in each group. The study group was treated with recombinant human interleukin-11 combined with cyclosporin. The controlgroup was treated with vinblastine combined with human immunoglobulins. Platelet was measured before treatment and 3, 7, 14, 21 days after treatment, and 1, 3, 5 and 12 months after treatment. Clinical efficacy and adverse reactions were observed in the two groups. Results Compared with the control group, before treatment and 3 days after treatment, the number of platelet increased in the study group, but the difference was not statistically significant（P〈0.05）. After treatment for 7, 14, 21 days, 1, 3, 5 and 12 months, compared with the control group, the platelet count of the study group patients increased, and the difference was statistically significant（P〈0.05）. After treatment of 1, 3, 5, 12 months, compared with control group, the team in patients with higher efficient, and each time period were statistically significant（P〈0.05）, a small number of patients with gastrointestinal symptoms, mild adverse reactions, such as liver and kidney function damage and increased blood pressure. Conclusion Recombinant human interleukin-11 combined with cyclosporine is safe and effective in the treatment of glucocorticoid ineffective ITP.
作者
罗神周
LUO Shenzhou(The Second Department of Internal Medicine of East Area, Lujiang County People＇s Hospital;)
出处
《中国卫生标准管理》
2018年第18期70-72,共3页
China Health Standard Management
关键词
原发免疫性血小板减少症
重组人白介素-11
环孢素
糖皮质激素
临床疗效
不良反应
primary immune thrombocytopenia （ITP）
recombinant humaninterleukin-11（rhIL-11）
cyclosporin a （CsA）
glucocorticoid
clinical efficacy
adverse reaction
